We are developing targeted, patient-specific therapies for some of the hardest-to-treat cancers. We aren’t satisfied with limited lifetime extensions. Our unique cancer-targeting agents and treatment approach offer the potential for truly curative responses in historically terminal diseases.
Evan has a PhD in medical physics and an MBA from the University of Wisconsin and has spent his career developing new technologies in nuclear medicine. He was formerly the president of Phoenix, a company developing particle accelerator technologies with applications in healthcare, energy, and defense. There he focused primarily on new technology and business development and financing, and both revenue and headcount at the company grew by >20X during his 10-year tenure. Evan helped lead the successful sale of Phoenix to SHINE Technologies in 2021 and subsequently served as the general manager of SHINE’s Phoenix Division and then as SHINE’s Chief Business Development Officer. He joined Archeus as CEO in 2022 and is focused on advancing its cancer-targeting agents into human clinical trials.
In addition to serving as Archeus' Chief Technology Officer, Reinier is an assistant professor of medical physics at the University of Wisconsin. He is a radiochemist with research interests focused on theranostics, targeted radionuclide therapy, and radio-immuno-oncology. He is the recipient of numerous academic awards, has an extensive publication record, and is the inventor on multiple patents for cancer treatment and imaging agents. He has a proven track record of designing novel cancer targeting agents and taking them from concept through in vitro and in vivo preclinical testing and into clinical translation. He has extensive experience developing and implementing diagnostic and therapeutic radiolabeling and radioanalytical methods using a broad range of isotopes in preclinical and clinical settings.
Dave is the founder of Casimir Jones, an intellectual property law firm. He has a JD from Stanford and a PhD in biochemistry from the University of Wisconsin. As an actively practicing IP attorney, he focuses on patent prosecution, post-issuance proceedings, litigation, litigation avoidance, due diligence, business counseling, and licensing with an emphasis in biotechnology, pharmaceuticals, chemicals, and medical devices. He has participated in the prosecution of over a thousand patent applications, many of which focus on cancer therapies, including targeted radionuclide therapy. He has significant experience and expertise in managing large, complex patent portfolios and positioning such portfolios for withstanding scrutiny in litigation and due diligence analysis associated with funding or acquisition events.
Jon Ohrn is the founder of PharmaShares Advisors and is currently an advisor at Rockefeller Capital Management. He previously spent four years with SVB Leerink as Managing Director, Mergers and Acquisitions. Before that, he spent 13-years at Deutsche Bank, most recently serving as a Managing Director of the Americas Mergers & Acquisitions team. Jon specializes in structuring extremely complex transactions involving tax matters, cross border situations and other forms of intricate consideration. Throughout his career, he has advised clients on numerous deals across industry sectors including media and entertainment and technology, with more than $50 billion in healthcare transactions to his credit.
Howard is a professor of medicine and the associate dean for oncology at the University of Wisconsin School of Medicine and Public Health and is the director of the University of Wisconsin Carbone Cancer Center. He is board certified in internal medicine and medical oncology, and his clinical practice focuses on the treatment of sarcomas and gynecologic malignancies. His research focuses on anti-cancer drug development, especially chemoprevention. Howard is the principal investigator of the UW Chemoprevention Consortium, an NCI-sponsored research network of universities that conduct Phase I and II clinical trials for chemopreventative agents. He has directed or participated in more than 100 clinical trials for cancer prevention and treatment, and he serves on the national committee which reviews all NCI-designated cancer centers.
Evan has a PhD in medical physics and an MBA from the University of Wisconsin and has spent his career developing new technologies in nuclear medicine. He was formerly the president of Phoenix, a company developing particle accelerator technologies with applications in healthcare, energy, and defense. There he focused primarily on new technology and business development and financing, and both revenue and headcount at the company grew by >20X during his 10-year tenure. Evan helped lead the successful sale of Phoenix to SHINE Technologies in 2021 and subsequently served as the general manager of SHINE’s Phoenix Division and then as SHINE’s Chief Business Development Officer. He joined Archeus as CEO in 2022 and is focused on advancing its cancer-targeting agents into human clinical trials.
In addition to serving as Archeus' Chief Technology Officer, Reinier is an assistant professor of medical physics at the University of Wisconsin. He is a radiochemist with research interests focused on theranostics, targeted radionuclide therapy, and radio-immuno-oncology. He is the recipient of numerous academic awards, has an extensive publication record, and is the inventor on multiple patents for cancer treatment and imaging agents. He has a proven track record of designing novel cancer targeting agents and taking them from concept through in vitro and in vivo preclinical testing and into clinical translation. He has extensive experience developing and implementing diagnostic and therapeutic radiolabeling and radioanalytical methods using a broad range of isotopes in preclinical and clinical settings.
Dave is the founder of Casimir Jones, an intellectual property law firm. He has a JD from Stanford and a PhD in biochemistry from the University of Wisconsin. As an actively practicing IP attorney, he focuses on patent prosecution, post-issuance proceedings, litigation, litigation avoidance, due diligence, business counseling, and licensing with an emphasis in biotechnology, pharmaceuticals, chemicals, and medical devices. He has participated in the prosecution of over a thousand patent applications, many of which focus on cancer therapies, including targeted radionuclide therapy. He has significant experience and expertise in managing large, complex patent portfolios and positioning such portfolios for withstanding scrutiny in litigation and due diligence analysis associated with funding or acquisition events.
Jon Ohrn is the founder of PharmaShares Advisors and is currently an advisor at Rockefeller Capital Management. He previously spent four years with SVB Leerink as Managing Director, Mergers and Acquisitions. Before that, he spent 13-years at Deutsche Bank, most recently serving as a Managing Director of the Americas Mergers & Acquisitions team. Jon specializes in structuring extremely complex transactions involving tax matters, cross border situations and other forms of intricate consideration. Throughout his career, he has advised clients on numerous deals across industry sectors including media and entertainment and technology, with more than $50 billion in healthcare transactions to his credit.
Howard is a professor of medicine and the associate dean for oncology at the University of Wisconsin School of Medicine and Public Health and is the director of the University of Wisconsin Carbone Cancer Center. He is board certified in internal medicine and medical oncology, and his clinical practice focuses on the treatment of sarcomas and gynecologic malignancies. His research focuses on anti-cancer drug development, especially chemoprevention. Howard is the principal investigator of the UW Chemoprevention Consortium, an NCI-sponsored research network of universities that conduct Phase I and II clinical trials for chemopreventative agents. He has directed or participated in more than 100 clinical trials for cancer prevention and treatment, and he serves on the national committee which reviews all NCI-designated cancer centers.
Jamey is a co-founder of Archeus and a professor of radiology at the University of Wisconsin with affiliate appointments in medical physics and pharmaceutics. He has a PhD in Medicinal Chemistry from the University of Michigan. He established UW-Madison’s Small Animal Imaging and Radiotherapy Facility and currently serves as its faculty director. Jamey is the lead scientist responsible for developing several of Archeus’ pipeline cancer imaging and therapy agents. He currently oversees a large research group that is responsible for much of the preclinical work underlying Archeus’ technologies, with focus areas in cancer-targeted molecular contrast agents, PET and CT imaging, and targeted radionuclide therapy. He has over 80 peer reviewed publications, is the co-inventor on more than 50 patents, and is the principal investigator on several major NIH grant programs. At Archeus, Jamey is responsible for scientific oversight of all preclinical research and pipeline development activities.
Zach is an associate professor and chair of the Department of Human Oncology at the University of Wisconsin. He is a Rhodes Scholar and completed an MD/PhD at Harvard’s Biological and Biomedical Sciences Program. Zach is a practicing physician with a clinical focus on the treatment of patients with melanoma and soft tissue sarcomas. He leads an independent translational research lab at UW-Madison focused on novel treatment approaches utilizing targeted radioisotope therapies. He is an active member of several professional societies and has an extensive publication record. He is actively involved in preclinical research with Archeus’ cancer-targeting agents and is leading the design and oversight of the company’s planned clinical trials.
Mike is the professor, chair in cancer imaging, and a member of the Translational Therapeutics Program at the Ohio State University Comprehensive Cancer Center. His research there focuses on new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging. Mike developed ProHance, the first nonionic macrocyclic MRI agent, which has been used in more than 50 million patients. He also invented the first catalysts for the production of technetium radiopharmaceutical kits for cardiac imaging and created some of the earliest targeted molecular imaging agents from monoclonal antibodies. He is an inventor on over 35 patents and has co-authored more than 100 peer reviewed publications. Before coming to the OSUCCC, he served as president and CEO of Bracco Research USA and as the head of the diagnostics R&D division of Bristol Meyers Squibb.
Norman is the chief medical officer and senior VP at Plus Therapeutics. He was previously chief medical officer and Senior VP at Jubilant Pharma, responsible for all pharma medical & regulatory affairs activities. Prior to Jubilant, he served as global chief medical officer at IBA Molecular and as senior VP, clinical development and chief medical officer at Molecular Insight Pharmaceuticals. Prior to industry, Norman practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is double board certified with fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the US along with active professional society memberships.
Wolfgang is a professor in the departments of radiation oncology and neurology and the director of medical physics for the Institute for Onco-Physics at the Albert Einstein College of Medicine. His research interests include whole brain radiotherapy, stereotactic radiosurgery, MR-guided radiotherapy, decision support systems for adaptive radiation therapy, and functional imaging for risk-adaptive radiotherapy and tumor response assessment. He is more specifically focused on hippocampal avoidance and preservation of neurocognitive function in patients with inoperable brain tumors requiring palliative radiation. Wolfgang has a prolific peer-reviewed publication record and is the inventor on multiple patents for technologies focused in cancer imaging and treatment.
Kevin has been a senior executive in the radiopharmaceutical industry for over 30 years with extensive product development and commercialization experience. He most recently served as president at Nordion, a Sotera Health Company. Prior to that, he was senior VP of marketing and sales for Nordion’s medical isotope business, including PET, SPECT, and therapeutic isotopes. Earlier in his career he held leadership roles in business development, strategy, and marketing at Jubilant Draximage, GE Healthcare’s Cardiovascular Radiopharmaceuticals division, and Bracco Diagnostics’ nuclear medicine business.
Jamey is a co-founder of Archeus and a professor of radiology at the University of Wisconsin with affiliate appointments in medical physics and pharmaceutics. He has a PhD in Medicinal Chemistry from the University of Michigan. He established UW-Madison’s Small Animal Imaging and Radiotherapy Facility and currently serves as its faculty director. Jamey is the lead scientist responsible for developing several of Archeus’ pipeline cancer imaging and therapy agents. He currently oversees a large research group that is responsible for much of the preclinical work underlying Archeus’ technologies, with focus areas in cancer-targeted molecular contrast agents, PET and CT imaging, and targeted radionuclide therapy. He has over 80 peer reviewed publications, is the co-inventor on more than 50 patents, and is the principal investigator on several major NIH grant programs. At Archeus, Jamey is responsible for scientific oversight of all preclinical research and pipeline development activities.
Zach is an associate professor and chair of the Department of Human Oncology at the University of Wisconsin. He is a Rhodes Scholar and completed an MD/PhD at Harvard’s Biological and Biomedical Sciences Program. Zach is a practicing physician with a clinical focus on the treatment of patients with melanoma and soft tissue sarcomas. He leads an independent translational research lab at UW-Madison focused on novel treatment approaches utilizing targeted radioisotope therapies. He is an active member of several professional societies and has an extensive publication record. He is actively involved in preclinical research with Archeus’ cancer-targeting agents and is leading the design and oversight of the company’s planned clinical trials.
Mike is the professor, chair in cancer imaging, and a member of the Translational Therapeutics Program at the Ohio State University Comprehensive Cancer Center. His research there focuses on new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging. Mike developed ProHance, the first nonionic macrocyclic MRI agent, which has been used in more than 50 million patients. He also invented the first catalysts for the production of technetium radiopharmaceutical kits for cardiac imaging and created some of the earliest targeted molecular imaging agents from monoclonal antibodies. He is an inventor on over 35 patents and has co-authored more than 100 peer reviewed publications. Before coming to the OSUCCC, he served as president and CEO of Bracco Research USA and as the head of the diagnostics R&D division of Bristol Meyers Squibb.
Norman is the chief medical officer and senior VP at Plus Therapeutics. He was previously chief medical officer and Senior VP at Jubilant Pharma, responsible for all pharma medical & regulatory affairs activities. Prior to Jubilant, he served as global chief medical officer at IBA Molecular and as senior VP, clinical development and chief medical officer at Molecular Insight Pharmaceuticals. Prior to industry, Norman practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is double board certified with fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the US along with active professional society memberships.
Wolfgang is a professor in the departments of radiation oncology and neurology and the director of medical physics for the Institute for Onco-Physics at the Albert Einstein College of Medicine. His research interests include whole brain radiotherapy, stereotactic radiosurgery, MR-guided radiotherapy, decision support systems for adaptive radiation therapy, and functional imaging for risk-adaptive radiotherapy and tumor response assessment. He is more specifically focused on hippocampal avoidance and preservation of neurocognitive function in patients with inoperable brain tumors requiring palliative radiation. Wolfgang has a prolific peer-reviewed publication record and is the inventor on multiple patents for technologies focused in cancer imaging and treatment.
Kevin has been a senior executive in the radiopharmaceutical industry for over 30 years with extensive product development and commercialization experience. He most recently served as president at Nordion, a Sotera Health Company. Prior to that, he was senior VP of marketing and sales for Nordion’s medical isotope business, including PET, SPECT, and therapeutic isotopes. Earlier in his career he held leadership roles in business development, strategy, and marketing at Jubilant Draximage, GE Healthcare’s Cardiovascular Radiopharmaceuticals division, and Bracco Diagnostics’ nuclear medicine business.
.jpg)
.jpg)
.jpg)
.jpg)